WYE-354

02/19/2020 - "This study provides evidence that WYE-354 is a substrate of the ABCB1 transporter, implicating that WYE-354 should be avoided for use in ABCB1-mediated MDR cancer."
02/19/2020 - "Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells."
10/13/2015 - "A short-term treatment with a higher dose of WYE-354 decreased the tumor size by 68.6% and 52.4%, in mice harboring G-415 or TGBC-2TKB tumors, respectively, compared to the control group. "
10/13/2015 - "Mice harboring subcutaneous gallbladder tumors, treated with WYE-354 or rapamycin, exhibited a significant reduction in tumor mass. "
08/01/2009 - "When injected into tumor-bearing mice, WYE-354 inhibited mTORC1 and mTORC2 and displayed robust antitumor activity in PTEN-null tumors. "

09/01/2016 - "Together, these pre-clinical results demonstrate the potent anti-colon cancer cell activity by WYE-354, and its activity may be further augmented with autophagy inhibition."
09/01/2016 - "In addition, WYE-354 treatment activated caspase-dependent apoptosis in the colon cancer cells. "
09/01/2016 - "We showed that WYE-354 was anti-survival and anti-proliferative when adding to primary (patient-derived) and established (HCT-116, HT-29, Caco-2, LoVo, and DLD-1 lines) colon cancer cells. "
09/01/2016 - "In the present study, we evaluated the potential anti-colon cancer cell activity by a novel mTORC1/2 dual inhibitor WYE-354. "

06/01/2019 - "WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines."

10/13/2015 - "Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice."